Skip to main content
. 2020 Oct;9(5):615–639. doi: 10.21037/hbsn.2019.09.13

Table 6. Summary current clinical trials using tumor-specific probes.

Tumor type Probe Clinical trial ID Title Institution Investigator n Design Dose Timing Fluorescence imaging system Comparator End points
CholangioCA Bevacizumab-800CW NCT03620292 Fluorescence image guided surgery in CholangioCA (COUGAR) University Medical Center Groningen Van Dam et al. 12 Open label dose finding 10, 25 or 50 mg of bevacizumab-800CW 3 days before surgery Not identified Dose Optimal dose of Bevacizumab-800CW; comparison of per-operative vs. ex-vivo analysis; detection of hilar cholangiocarcinoma intraoperatively; probe distribution; fluorescence signal in surrounding tissue
Pancreatic cancer Panitumumab-IRDye800 NCT03384238 Panitumumab-IRDye800 in patients with pancreatic cancer undergoing surgery Stanford University Rosenthal et al. 24 Open label single arm Not identified 2–5 days before surgery Novadaq devices: SPY/LUNA, Pinpoint, IR9000 fluorescence imaging system, and/or SurgVision Explorer Air Not applicable Tumor-to-background ratio; adverse events; number of positive lymph nodes not detected by white light; number of positive resection margins not detected by white light
Pancreatic cancer and metastatic colorectal cancer SGM-101 NCT02973672 Phase I of SGM-101 in patients with cancer of the colon, rectum or pancreas Center for human drug research, Netherlands, Leiden University Medical Center, Erasmus Medical Center Burffraaf et al. 60 Open label single arm Not identified 4 days before surgery Not identified Not applicable Rate of adverse events; tumor-to-background ratio; serum SGM-101 concentration
Pancreatic cancer Bevacizumab-800CW NCT02743975 Near-infrared image guided surgery in pancreatic adenocarcinoma (PENGUIN) University Medical Center Groningen Van Dam et al. 26 Open label dose finding 4.5, 10, 25, or not 50 mg of bevacizumab-800CW Not identified Not identified Dose Mean fluorescence intensity in tumor vs. normal tissue; optimal dose; adverse events
Pancreatic cancer Cetuximab-800CW NCT02736578 Cetuximab-IRDye 800CW and intraoperative imaging in finding pancreatic cancer in patients undergoing surgery Stanford University Rosenthal et al. 8 Open label parallel arm 50 vs. 100 mg loading dose of unlabeled cetuximab, 50 vs. 100 mg of labeled cetuximab 2–5 days before surgery Not identified Dose Assess dye uptake in tumor vs. non-cancerous tissue; measure fluorescence intensity; effect of dose on fluorescence intensity; sensitivity and specificity; detection in LNs; signal to noise ratios (ex vivo); signal to noise ratio (in vivo); toxicity

CholangioCA, cholangiocarcinoma.